This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 6
th Annual OneMedForum San Francisco 2013, which will be held at the Sir Francis Drake Hotel in San Francisco.
Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Tuesday, January 8
th at 9:40 am PST in the Franciscan Room.
Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon
1 is being studied in clinical trials for 17 vaccine indications. They include:
Phase 3: GSK's RTS,S for malaria 2
Phase 3: GSK's MAGE-A3 for non-small cell lung cancer 2
Phase 3: GSK's MAGE-A3 for melanoma 2
Phase 3: GSK's Zoster Herpes for shingles 2
Phase 2: Janssen's ACC-001 for Alzheimer's disease
Agenus pipeline programs include:
Phase 2: Prophage Series G-100 for newly diagnosed glioma
Phase 2: Prophage Series G-200 for recurrent glioma
Phase 2 : HerpV (contains QS-21 Stimulon) for genital herpes
Saponin Platform: QS-21 Stimulon® Adjuvant
Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
Heat Shock Protein Platform: Prophage Series G
The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months.
Heat Shock Protein Platform: Recombinant Series HerpV
HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks.